Kexing Biopharm Co., Ltd. (SHA:688136)

China · Delayed Price · Currency is CNY

21.53

-0.41 (-1.87%)

Oct 14, 2026, 11:29 AM CST

Market Cap	4.28B -45.5%
Revenue (ttm)	1.44B +6.9%
Net Income	209.17M +109.3%
EPS	1.06 +110.1%
Shares Out	198.59M
PE Ratio	20.71
Forward PE	35.39
Dividend	0.25 (1.16%)
Ex-Dividend Date	Jun 15, 2026

Volume	2,958,998
Open	21.80
Previous Close	21.94
Day's Range	21.31 - 21.96
52-Week Range	17.00 - 41.50
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Kexing Biopharm

Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields. It also develops GB05, a human interferon a1b... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1997

Employees 1,109

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688136

Full Company Profile

Financial Performance

In 2025, Kexing Biopharm's revenue was 1.53 billion, an increase of 9.03% compared to the previous year's 1.41 billion. Earnings were 155.57 million, an increase of 394.17%.

Financial Statements